E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
We investigate the efficacy of commercially available interleukin-6 receptor antibody 'RoActemra' for reducing the systemic inflammatory response in patients having been resuscitated after out-of-hospital cardiac arrest. This study is a double-blind, randomized pilot trial. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients having been resuscitated from out-of-hospital cardiac arrest have a high 30 day mortality partly caused by a systemic inflammatory response. We hope to suppress this response with RoActemra. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10007515 |
E.1.2 | Term | Cardiac arrest |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to determine the efficacy of an IL-6 receptor antibody (IL-6RA) compared with placebo on the endpoint of daily high-sensitivity c-reactive protein (hsCRP) measurements from admission (i.e. prior to initiation of study drug) to the first 72 hours after admission in patients admitted after resuscitated OHCA.
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are to determine the effects of an IL-6RA on inhibition of inflammation, cardiac protection, neuroprotection, renal protection, endothelial protection, clinical endpoints including survival and neurological outcome, as well as safety. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
1) A subgroup of 24 patients will be randomized to cardiac and cerebral magnetic resonance (MR) imaging the day following admission and 3 months after admission. The intervention will be administered exactly as dictated by the main trial. Therefore, participation in a sub-study will have no impact on the IMP use. |
|
E.3 | Principal inclusion criteria |
1) Age ≥ 18 years 2) Out-of-hospital cardiac arrest of a presumed cardiac cause 3) Unconsciousness upon admission 4) Sustained return of spontaneous circulation for more than 20 minutes
|
|
E.4 | Principal exclusion criteria |
1) Consciousness upon admission 2) Presumed non-cardiac cause of arrest 3) Unwitnessed asystole 4) Suspected or confirmed intracranial bleeding or stroke 5) Pregnancy, or females in fertile age, unless a negative serum HCG can rule out pregnancy within the inclusion window. 6) Temperature on admission < 30 °C 7) Persistent cardiogenic shock that is not reversed within the inclusion window 8) Known disease making 180 day survival unlikely 9) Known limitations in therapy 10) Known pre-arrest Cerebral Performance Category of 3 to 4 11) > 240 minutes from ROSC to randomization 12) Known allergies to IL-6RA 13) Known infection 14) Known hepatic cirrhosis
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Daily measurements of hsCRP from admission to 72 hours after admission |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
hsCRP will be measured daily from admission to 3 days after admission |
|
E.5.2 | Secondary end point(s) |
Markers of inflammation: Daily interleukin levels (IL-1b, IL-6, IL-10, IL-13, TNF-α) from admission to 72 hours after admission Daily differential count the first 3 days from admission Daily Sequential Organ Failure Assessment (SOFA) scores the first 3 days from admission
Markers of cardiac injury: Daily troponin T (TnT) and CKMB levels the first 3 days from admission
Markers of hemodynamic function: Daily Swan-Ganz based measurements of cardiac output, central venous pressure, pulmonary capillary wedge pressure, and systemic vascular resistance Bihourly analyses of arterial blood gas the first 36 hours
Markers of cerebral injury: Neuron-specific enolase (NSE) levels after 48 and 72 hours
Markers of kidney injury: Daily creatinine levels the first 3 days from admission Markers of hepatic injury:
Daily measurements of ALAT, ASAT, bilirubin, INR the first 3 days from admission
Markers of endothelial injury: Daily soluble thrombomodulin levels the first 3 days from admission
Clinical endpoints: Survival at 30 days, 90 days, 180 days, and at end of trial Montreal Cognitive Assessment (MOCA) score at 90 days Cerebral Performance Category (CPC) at 30 days, 90 days and 180 days Safety: Cumulated incidence of adverse events the first 7 days
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Evaluation of paraclinical endpoints (markers of organ dysfunction) up to three days after admission.
Evaluation of clinical endpoints (survival/function) finished 180 days after admission. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last contact to the subject will be 6 months (+/- 2 weeks) after last randomization. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |